T~~;,r,, ~nycoses II;,VC. l,c,t~~ described in a pre\ious this drug in di\rided closes at six-hour intervals is rcbport.
usually sufficient to maintain a serum level of from clicmothcrapy is inclicatecl, the following 9-12 mg/ 100 ml. Supplemental therapy \vith ampiagents itrr recommended (Table 1 ) .
cillin, 500 mg cvery six hours is recommended some. In patients \i~ho are allergic to ampicillin.
PESIC:II>LIS c!,closc,rinc. or h!-droxystilbamidine isethionitte may
1'c.nicillin is thv antibiotic of choice for the c l~c ,~n o t h (~a p y of uctinorn~~cosis. The drug should bc3 administcretl in doses of 2 to 6 million units daily and continuc~tl for 6 to 18 months. If surgen is recluiretl, it shoulcl I,e performed under antil~iotic covc1ragc.
In pilticwts \vho itre allergic to penicillin. a varic,ty of othcr agents ha\.e pro\.ed to be useful but gcbnc*rally so~nc.\vhat lcss effective. These drugs includc lincom!rcin. tetracycline, erythromycin, chloramphenicol. chlortetracycline ( Aureom ycin ) and osytetri~c!.clinc ( Trrram!.cin ). Streptomycin and sulfittliazinc. ;ire, of lesser valuc. As a g e~~c r a l rule, an!. itgent \vhich is effective against Gram-positive I~acteria can be expected to have about the same relati\.e r4'ectiveness in the treatment of actinomycosis.
.\lVmbcrs of the sulfonamide group, but notably sulfadiazinc, arc rcconimendecl in patients with Hydroxystilbamidine isethionatc (2-hydrosystilhamidine) is a useful agent in the treatment of patients with Sorth American blastomycosis. Selection of cases seems important and those patients ~vith skin lesions or non-cavitary pulmonary lesions appear to respond best.
Hydrosystilbamicline isethionate is supplied in a 20 ml ampule containing 225 mg sterile powder. This po\vder is dissolved immediately prior to use in 200 to 300 ml of either 5 percent glucose or normal saline solution. Solutions that are turbid after dissolving should be discarded. Both the ampule and the prepared solution must be protected from light and heat by slipping a black cover or paper bag o\.cr the infusion bottle. The recommended daily close is 825 mg atlministerecl intravenously in not less thiun :30, and usually not more than 90, minutes. formication, weakness, headache, myalgia, anorexia, percent glucose solution in a concentration not nausea, vomiting, diarrhea, chills or fever. If the esceeding 10 mg1100 ml. The initial dose is usually solution is given too quickly, patients may develop considered to be 0.25 mg/kg of body weight, but dizziness, pruritus, tachycardia or circulatory colmany physicians prefer to start treatment with lapse. Hepatitis is an uncommon but potentially much smaller amounts. Doses are increased over a serious complication. Patients should be monitored period of approximately one to three weeks to the prior to and during therapy by serial determinations usual maximum daily amount of 1 mglkg of body of serum glutamic-oxaloacetic transaminase.
CHEMOTHERAPEUTIC AGENTS FOR THE PULMONARY MYCOSES
weight. However, it must be emphasized that this The recommended total dose for a course of daily dose is often not attainable and much smaller therapy is usually 8-16 grams. Following cessation doses are frequently therapeutically effective. Intraof treatment, skin and pulmonary lesions usually venous infusions are given daily, every other day or continue to improve as a result of the release of the three times weekly over a one to four hour period. drug from stores in the body, notably in the liver Total dose and duration of therapy depends on the and kidney. specific disease being treated. COMMllTEE ON FUNGUS DISEASE arbitrary course of ten weeks' therapy should be administered with dosage individualized to achieve serum levels double those required for the inhibition i n t;itro of the causative fungus. Such therapy has been notably successful in chronic histoplasmosis, hut is ilsually neither practical nor necessary. L,ocal amphotericin B ( 1 mg/ ml ) has generally produced good results in the treatment of sinuses and lesions of bone, skin, synovial membranes and scrous cavities. The drug is administcred either by direct injection or by means of a special drip arrangement.
In meningitis, ~~mphotericin B may be given by the intrathecal route or preferably into the cisternal space or into an intraventricular device (Ommaya reservoir). The latter method is usually reserved for patients with intc.rnal hydrocephalus. The usual dose by this route varies from 0.1 mg to 1 mg per injection. In coccidioidal meningitis intrathecal therapy must bc. continued for a prolonged period of time, and this is usually measured in years.
The administration of amphotericin B is attended by serious and distressing side effects. Almost invariably chills, fever, anorexia and vomiting are encountered. \\'ith intravenous administration, phlebitis is frequently a problem and 10-25 mg of heparin in the solution may be necessary to prevent this carnp1ic;ition. Hypokalemia is a frequent and trou-1)lesome clinical problem, and supplemental oral potassium is recommended. Moderate self-limited anemia is frequently seen and has been attributed lmth to hemolysis and to direct bone marrow suppression. The major toxic effect of the drug, howevc,r, is on the kidneys with azotemia almost invariably present. The renal canvoluted tubules and glomeruli are involved, and extensive nephrociilcinosis usually results. Henal damage usually is dose-related and may be anatomically but not necessarily physiologically progressive for as long as two years following cessation of therapy. Such impaired function becomes more severe with total doses of over 2 grams and is a serious problem with a dose over 6 grams. Creatinine clearance tests are considered to be more useful and more apt to reflect the true status of renal function than blood urea nitrogen determinations. Renal tubular acidosis has been reported and concurrent alkali therapy may be useful. To control nausea, vomiting, fever, and chills, salicylittes and antihistamines have been recommended. Corticosteroids are helpful agents in selected cases. In low doses and with concomitant chemotherapy they do not cause flare up or spread of mycotic disease and have been used to suppress toxic effects of therapy and severe allergic manifestations of the primary disorder.
It appears virtually certain that this drug will shortly be released for general usage. It has been found effective in patients with pulmonary cvptococcosis and even with such more severe manifestations as meningitis. It has also produced very favorable results in patients with severe Candida infections. It is given by the oral route and the currently recommended dose is 150 mglkg per day administered in four equally divided amounts. The duration of therapy has been from 6 to 12 weeks. Nearly 100 patients have been given the drug and side effects have been few. Leukopenia occurred in one case, but there were important other causes for this development in this patient.
Saramycetin, a polypeptide antibiotic, has been found useful in patients with histoplasmosis and t~lastomycosis. It is given by the subcutaneous route in a dosage of 4-8 mg/kg per day in four divided doses. It has been well tolerated by the patients and the only notable side effect has been a delay in excretion of sulfobromophthalein in virtually all cases. A minimal to mild rise in serum bilirubin is also seen in some patients. Problems in the production of the drug have not yet been solved and there is no expectation at this moment that the drug will be released for general usage.
Hamycin, a polylene antifungal agent, like amphotericin B, has been used in limited trials in patients with histoplasmosis and blastomycosis. It appears to be active in some patients. The attractive features of the drug are the oral route of administration and the failure, so far, to detect any impairment in renal function. However, in animals the drug, by the parenteral route, is more toxic than amphotericin B. Side effects in man have been mainly those of nausea, vomiting and diarrhea. The dosage of the drug and the ultimate preparation have not yet been determined, but experimental studies are going on with an enteric coated preparation in amounts of 2-4 mglkg per day in four divided doses.
